Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* HCV RNA \> 15 IU/mL at screening~* HCV genotype 1 or 4~* Chronic HCV infection (≥ 6 months)~* Prior virologic failure after treatment with SOF in combination with simeprevir (SMV) ± RBV or with RBV ± pegylated interferon (PEG)~* Cirrhotic and non-cirrhotic as determined by standard methods~* Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~Key Exclusion Criteria:~* Prior exposure to approved or experimental non-structural protein (NS5A) inhibitors~* Prior exposure to nucleos(t)ide polymerase inhibitors, other than SOF~* Pregnant or nursing female or male with pregnant female partner~* Coinfection with HIV or hepatitis B virus~* Current or prior history of clinical hepatic decompensation~* Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 weeks, without cirrhosis (Type: EXPERIMENTAL): LDV/SOF for 12 weeks
- LDV/SOF + RBV 12 weeks, without cirrhosis (Type: EXPERIMENTAL): LDV/SOF + RBV for 12 weeks
- LDV/SOF + RBV 12 weeks, with compensated cirrhosis (Type: EXPERIMENTAL): LDV/SOF + RBV for 12 weeks
- LDV/SOF 24 weeks, with compensated cirrhosis (Type: EXPERIMENTAL): LDV/SOF for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).